Avelumab and Merkel Cell Carcinoma: Examining Causation and Risk
From General Health to Occupational Exposure
The legacy of general health and science information has long emphasized broad population-level wellness, from dietary patterns and weight management to systematic medical surveillance. These foundations established rigorous frameworks for data collection, outcome definition, and timely dissemination—tools essential for understanding how environmental and behavioral factors shape public health. Within this heritage, occupational health emerged as a natural extension, applying similar epidemiological rigor to workplace exposures. The transition from general health contexts to specific occupational concerns requires careful attention to exposure pathways and their potential consequences. In mass production settings, workers may encounter substances that warrant focused investigation through established surveillance methodologies. One such area involves the therapeutic agent Avelumab, an immune checkpoint inhibitor used in oncology. While its primary context is clinical, occupational exposure during manufacturing or handling raises distinct questions. The pivot from general health literacy to occupational exposure concern centers on how workers in production environments might experience unintended contact with pharmaceutical compounds. This shift demands the same systematic approach—defining target populations, standardizing outcome definitions, and ensuring timely data collection—that characterized earlier public health efforts. The focus narrows from population-wide wellness to the specific risks associated with handling active pharmaceutical ingredients in industrial settings.
Bridge: Avelumab as a Therapeutic Agent
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the JAVELIN Merkel 200 phase II trial, where confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). This makes avelumab the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).
Merkel Cell Carcinoma: Disease Characteristics and Risk Factors
Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease is characterized by high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).
Mechanistic Pathway: Therapeutic vs. Causative
The mechanistic pathway linking avelumab to Merkel cell carcinoma is primarily therapeutic rather than causative. Avelumab is used to treat MCC by blocking PD-L1, thereby enhancing the immune system's ability to attack cancer cells. However, checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case described hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, which was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This indicates that while avelumab can trigger immune-related complications, it does not cause MCC; rather, it is a treatment for the disease.
Risk Context and Clinical Management
For patients who are refractory to avelumab, alternative treatment options are limited. In a multicenter study, patients with metastatic MCC refractory to avelumab were treated with combined ipilimumab and nivolumab, and three out of five patients responded according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another retrospective study confirmed that ipilimumab plus nivolumab can be effective in anti-PD-L1/PD-1 refractory MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). These findings highlight that avelumab-refractory disease remains a clinical challenge, but subsequent immune checkpoint inhibitor combinations may offer benefit. Regarding risk anchors, the adequacy of warnings about avelumab and MCC is addressed through its approved indication for treating metastatic MCC, which is clearly stated in prescribing information. The risk of immune-related adverse events is well-documented, but there is no evidence suggesting that avelumab causes MCC. Instead, it is a therapeutic agent for an existing condition. Causation-related considerations for affected patients focus on the fact that avelumab is used to treat MCC, not to induce it. The timeline between exposure and documented harm typically involves immune-related adverse events occurring during treatment, as seen in the sarcoidosis reactivation case (https://pubmed.ncbi.nlm.nih.gov/31543781/). There is no evidence of avelumab causing de novo MCC; rather, it is a treatment for patients already diagnosed with the disease.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
Does avelumab cause Merkel cell carcinoma?
No, avelumab is a treatment for Merkel cell carcinoma, not a cause. It is an immune checkpoint inhibitor that targets PD-L1 to help the immune system attack cancer cells. While it can cause immune-related adverse events, there is no evidence that it induces de novo Merkel cell carcinoma.
What are the risks of avelumab therapy?
Avelumab can cause immune-related adverse events due to overactivation of the immune system, such as reactivation of sarcoidosis leading to hypercalcaemia (https://pubmed.ncbi.nlm.nih.gov/31543781/). These events are generally manageable with corticosteroids. The prescribing information includes warnings about these risks.
What treatment options exist for patients who progress on avelumab?
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.